151 related articles for article (PubMed ID: 36863395)
1. Expression and Release of Tumor Cell Tissue Factor Triggers Recurrent Thromboembolism in a Patient with Endometrial Cancer.
Beckmann L; Lennartz M; Poch A; Holstein K; Bokemeyer C; Langer F
Hamostaseologie; 2023 Aug; 43(4):289-296. PubMed ID: 36863395
[TBL] [Abstract][Full Text] [Related]
2. Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy.
Abu Saadeh F; Langhe R; Galvin DM; O Toole SA; O'Donnell DM; Gleeson N; Norris LA
Thromb Res; 2016 Mar; 139():135-41. PubMed ID: 26916311
[TBL] [Abstract][Full Text] [Related]
3. Treatment for superficial thrombophlebitis of the leg.
Di Nisio M; Wichers IM; Middeldorp S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD004982. PubMed ID: 29478266
[TBL] [Abstract][Full Text] [Related]
4. Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial.
Khorana AA; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Lee AY
J Clin Oncol; 2017 Apr; 35(10):1078-1085. PubMed ID: 28029329
[TBL] [Abstract][Full Text] [Related]
5. Role of current and emerging antithrombotics in thrombosis and cancer.
Mousa SA
Drugs Today (Barc); 2006 May; 42(5):331-50. PubMed ID: 16801996
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update.
Franco-Moreno A; Cabezón-Gutiérrez L; Palka-Kotlowsa M; Villamayor-Delgado M; García-Navarro M
J Thromb Thrombolysis; 2019 Apr; 47(3):409-419. PubMed ID: 30467760
[TBL] [Abstract][Full Text] [Related]
7. Deep venous thrombosis.
López JA; Kearon C; Lee AY
Hematology Am Soc Hematol Educ Program; 2004; ():439-56. PubMed ID: 15561697
[TBL] [Abstract][Full Text] [Related]
8. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
Thachil J
Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488
[TBL] [Abstract][Full Text] [Related]
9. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
10. Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence.
Jiménez-Fonseca P; Gallardo E; Arranz Arija F; Blanco JM; Callejo A; Lavin DC; Costa Rivas M; Mosquera J; Rodrigo A; Sánchez Morillas R; Vares Gonzaléz M; Muñoz A; Carmona-Bayonas A
Eur J Intern Med; 2022 Jun; 100():33-45. PubMed ID: 35227541
[TBL] [Abstract][Full Text] [Related]
11. Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin.
Gezelius E; Flou Kristensen A; Bendahl PO; Hisada Y; Risom Kristensen S; Ek L; Bergman B; Wallberg M; Falkmer U; Mackman N; Pedersen S; Belting M
PLoS One; 2018; 13(11):e0207387. PubMed ID: 30412630
[TBL] [Abstract][Full Text] [Related]
12. A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - A real world experience.
Phelps MK; Wiczer TE; Erdeljac HP; Van Deusen KR; Porter K; Philips G; Wang TF
J Oncol Pharm Pract; 2019 Jun; 25(4):793-800. PubMed ID: 29460705
[TBL] [Abstract][Full Text] [Related]
13. Trousseau's syndrome: cancer-associated thrombosis.
Ikushima S; Ono R; Fukuda K; Sakayori M; Awano N; Kondo K
Jpn J Clin Oncol; 2016 Mar; 46(3):204-8. PubMed ID: 26546690
[TBL] [Abstract][Full Text] [Related]
14. [Cancer and venous thromboembolism].
Meyer G; Belmont L
Rev Mal Respir; 2011 Apr; 28(4):443-52. PubMed ID: 21549900
[TBL] [Abstract][Full Text] [Related]
15. Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice.
van der Wall SJ; Klok FA; den Exter PL; Barrios D; Morillo R; Cannegieter SC; Jimenez D; Huisman MV
J Thromb Haemost; 2017 Jan; 15(1):74-79. PubMed ID: 28012224
[TBL] [Abstract][Full Text] [Related]
16. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer.
Lee JH; Oh YM; Lee SD; Lee JS
J Korean Med Sci; 2019 Jun; 34(21):e160. PubMed ID: 31144482
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
Cochrane Database Syst Rev; 2011 Jun; (6):CD006649. PubMed ID: 21678360
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
Cochrane Database Syst Rev; 2011 Feb; (2):CD006649. PubMed ID: 21328285
[TBL] [Abstract][Full Text] [Related]
20. An Update in Anticoagulant Therapy for Patients with Cancer-Associated Venous Thromboembolism.
Martins MA; Silva TF; Fernandes CJ
Curr Oncol Rep; 2023 May; 25(5):425-432. PubMed ID: 36928825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
